Acceleron Pharma (XLRN) & Cellular Biomedicine Group (CBMG) Financial Comparison

Acceleron Pharma (NASDAQ:XLRN) and Cellular Biomedicine Group (NASDAQ:CBMG) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Acceleron Pharma and Cellular Biomedicine Group, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acceleron Pharma 0 5 8 0 2.62
Cellular Biomedicine Group 0 1 1 0 2.50

Acceleron Pharma presently has a consensus price target of $56.30, indicating a potential upside of 11.13%. Cellular Biomedicine Group has a consensus price target of $38.00, indicating a potential upside of 110.18%. Given Cellular Biomedicine Group’s higher probable upside, analysts clearly believe Cellular Biomedicine Group is more favorable than Acceleron Pharma.

Earnings and Valuation

This table compares Acceleron Pharma and Cellular Biomedicine Group’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acceleron Pharma $13.48 million 173.59 -$108.45 million ($2.68) -18.90
Cellular Biomedicine Group $340,000.00 978.45 -$25.49 million ($1.78) -10.16

Cellular Biomedicine Group has lower revenue, but higher earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than Cellular Biomedicine Group, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

93.1% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 8.3% of Cellular Biomedicine Group shares are owned by institutional investors. 3.9% of Acceleron Pharma shares are owned by company insiders. Comparatively, 8.3% of Cellular Biomedicine Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Acceleron Pharma and Cellular Biomedicine Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acceleron Pharma -807.36% -32.69% -30.94%
Cellular Biomedicine Group -13,988.39% -44.62% -41.84%

Risk and Volatility

Acceleron Pharma has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Cellular Biomedicine Group has a beta of 3.45, indicating that its share price is 245% more volatile than the S&P 500.

About Acceleron Pharma

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis. It also engages in the research and production of lab kits. The company has a strategic research collaboration with GE Healthcare Life Science to co-develop industrial control processes in chimeric antigen receptor T-cell and stem cell manufacturing; and Novartis to manufacture and supply the CAR-T cell therapy KymriahÂ. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in Cupertino, California.

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply